motolimod   Click here for help

GtoPdb Ligand ID: 9026

Synonyms: VTX-2337
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Motolimod is an investigational Toll-like receptor 8 (TLR8) agonist [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 79
Molecular weight 458.27
XLogP 4
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCCN(C(=O)C1=Cc2ccc(cc2N=C(C1)N)c1ccc(cc1)C(=O)N1CCCC1)CCC
Isomeric SMILES CCCN(C(=O)C1=Cc2ccc(cc2N=C(C1)N)c1ccc(cc1)C(=O)N1CCCC1)CCC
InChI InChI=1S/C28H34N4O2/c1-3-13-31(14-4-2)28(34)24-17-23-12-11-22(18-25(23)30-26(29)19-24)20-7-9-21(10-8-20)27(33)32-15-5-6-16-32/h7-12,17-18H,3-6,13-16,19H2,1-2H3,(H2,29,30)
InChI Key QSPOQCXMGPDIHI-UHFFFAOYSA-N
References
1. Chow LQM, Morishima C, Eaton KD, Baik CS, Goulart BH, Anderson LN, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM et al.. (2017)
Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.
Clin Cancer Res, 23 (10): 2442-2450. [PMID:27810904]
2. Dietsch GN. (2016)
Motolimod effectively drives immune activation in advanced cancer patients.
Oncoimmunology, 5 (5): e1126037. [PMID:27467937]
3. Lu H, Dietsch GN, Matthews MA, Yang Y, Ghanekar S, Inokuma M, Suni M, Maino VC, Henderson KE, Howbert JJ et al.. (2012)
VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.
Clin Cancer Res, 18 (2): 499-509. [PMID:22128302]